Sector News

Biopharma veterans go in on oncology company that will tackle treatment gaps

January 27, 2018
Life sciences

Biopharma veterans Robert Mulroy and Debasish Roychowdhury launched Partner Therapeutics, an oncology company that will specialize in bringing approved and late-stage therapies to the patients who need them.

Mulroy, who resigned as Merrimack Pharmaceuticals CEO in October 2016, will take the reins at Partner Therapeutics, or PTx, according to a statement. And Roychowdhury, PTx’s chief medical officer, previously served as clinical development VP at GlaxoSmithKline, headed the oncology unit at Sanofi and led the global oncology regulatory group at Eli Lilly.

The duo will tap their biopharma expertise—which spans drug discovery, development, approval and launch, capital raises and financial transactions—to develop and commercialize approved and late-stage treatments with the ultimate goal of boosting outcomes and cutting the cost of care.

“We formed PTx to address gaps in treatment and improve cost effectiveness of cancer care through a mission-driven organization focused on exceptional execution on behalf of patients,” Mulroy said.

Unlike your average oncology startup, which zeroes in on a target or targets and seeks to carry its prospects through development, PTx will assemble its portfolio by acquiring promising programs, the company said. And it will cover the whole spectrum of cancer treatment, from primary therapies to supportive care.

“We are committed to building a company that serves as a true partner to improve patient care,” said Roychowdhury. “We believe PTx can serve as a critical link between the investigators pushing the boundaries of our understanding of cancer and the healthcare professionals working to achieve the best outcomes for each and every patient.”

By Amirah Al Idrus

Source: Fierce Biotech

comments closed

Related News

January 15, 2022

Colorcon Ventures invests in AI-Driven bio-simulation company VeriSIM Life

Life sciences

Colorcon Ventures, the corporate venture fund of Colorcon Inc., has invested in VeriSIM Life, a San Francisco-based startup with a digital bio-simulation platform that accelerates drug development and reduces animal testing.

January 15, 2022

A record number of biotechs are going public. Here’s how they’re performing.

Life sciences

Initial public offerings have fueled biotech’s boom. Keep track of them as they happen with this database. Which biotechs create value over time, and which fail? What types of companies are generating the best returns? Who are their top investors? Biopharma Dive is tracking these details in the database which will be updated regularly.

January 15, 2022

Sanofi cuts ties with Sangamo, sharpening focus on ‘off-the-shelf’ cell therapy

Life sciences

Sanofi has ended a long-running alliance with Sangamo Therapeutics to develop genetic medicines for inherited blood disorders, among them an experimental sickle cell disease therapy that is in early clinical testing.
The two have been developing complex, personalized treatments, led by a sickle cell drug known as SAR445136. But Sanofi is now more interested in off-the-shelf approaches, which are meant to be more convenient.

Send this to a friend